Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. - Wikidata - wikimedia - TriplyDB

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.

http://www.wikidata.org/entity/Q34492346

about

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease Integrated genetic and pharmacologic interrogation of rare cancers CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Long non-coding RNA EWSAT1 promotes human nasopharyngeal carcinoma cell growth in vitro by targeting miR-326/-330-5p.Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.Cell cycle proteins as promising targets in cancer therapy Transcriptional Addiction in Cancer.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Super-Enhancer-Driven Transcriptional Dependencies in Cancer.Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.CDK4 expression in chordoma: A potential therapeutic target.Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm.CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma.Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations.Targeting Super-Enhancers for Disease Treatment and Diagnosis.

P2860

Q26775306-A2FDEB01-8EC7-4D5F-8156-534D263E03C2 Q28829289-DA9AA214-E85A-4DC4-83BE-A0C8DF4D998F Q33759276-4AE2227A-8402-4E89-B8DE-EDF65A241774 Q36562082-6E540A5F-F554-4056-9564-347D0EEC8E56 Q37530948-2574D5FA-516F-4C29-B145-535F06E6B959 Q37665228-23C636A1-0A10-4253-ADF0-12C97B6539FD Q37693690-77E114DE-66FB-4BE9-8869-38F1405B1C1A Q39130428-EB1C15DD-5F05-47C1-A311-33F29CB796F5 Q39183079-5D45C964-A7F6-4A29-B25C-25A676AB1302 Q39441366-D017D15D-79E0-4683-8264-4D9D867D7BD9 Q42126638-BB78FC21-9BD0-4EBF-968B-71168FC86749 Q46131586-DDDE52F3-2B77-476C-828F-682BC11268AB Q46167320-A7E06C55-4FE0-4689-8E4D-916A86888D90 Q47130816-8F7417ED-A4E0-40FF-A36E-84B59A267251 Q47384424-13353996-8B37-476A-A293-9624BF9CFDF1 Q47554260-7ED7624B-1221-49F9-9CA1-ACA7FC20A13B Q51061820-42157D2D-EEF6-466F-B316-2C02933D76F1 Q55033636-548104FC-BCE8-4735-A081-4DD93F328B36 Q55454424-ADE2688B-7EF5-4981-BA5F-80174DD96F40

P2860

Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.

http://www.wikidata.org/entity/Q34492346

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@ast

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@en

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@nl

type

label

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@ast

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@en

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@nl

prefLabel

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@ast

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@en

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@nl

P1433

Q34492346-0353F08F-F7C2-438E-9391-42F0B982B736

P1476

Q34492346-5A1A1293-D690-42FC-B4F4-E2D8B6D4EA56

P2093

Q34492346-022DCF7F-48F9-43EC-BC1B-C064BEFFF211

Q34492346-50CE794F-44BF-40A2-A67D-B1E8BE3D6AF6

Q34492346-6050A9C8-F663-4CAC-80EC-61B6582A5467

Q34492346-68465EA2-0FE9-4627-B8CD-767C763AF9E9

Q34492346-6E10479E-AAB8-47B1-8963-39EC1BB37454

Q34492346-70E13B8C-8E55-4A08-809B-ED377EB0C0F8

Q34492346-89A77557-952B-47B0-B223-408E53EB8AD1

Q34492346-A4FE8516-5DEE-4F3D-87C5-9F54F9AF1EAF

Q34492346-C9905BD2-814C-436D-95B2-E38809610139

Q34492346-DD917323-CC42-4366-9714-9D23DD120DEF

P2860

Q34492346-052C0AD8-9545-44A8-8512-F2EAF2ECFB92

Q34492346-05908B0E-5852-4BA7-9612-48F88E2670E2

Q34492346-09038F17-F19E-4F01-8AB1-FEB81A8CC6D7

Q34492346-0B88062C-3245-450E-B517-F81D731327BC

Q34492346-174A2745-D6BA-4CEA-B744-BD0D8AFD8070

Q34492346-187DDFA9-562B-4087-AB3C-13BC2576C5DB

Q34492346-1F7B6B70-1A0C-49A8-9050-09F510570E0B

Q34492346-1FE59CFB-EE4D-4FAF-9C31-6F2F6C38AA77

Q34492346-226AAF6A-20CB-47CA-B1D9-DAF961FBB5E2

Q34492346-2957EF67-3603-4E69-A4FD-51EDFA6BEC9A

P304

Q34492346-2031ED06-4779-445D-94E3-38B39FC9961D

P31

Q34492346-B99E394D-1652-459A-8DE8-A431E3722E32

P356

Q34492346-E8EEFEF4-D81E-432D-A830-19E2D41EEB7C

P407

Q34492346-E84F7584-CB9F-42B0-BA0F-08F0C3EDDCC2

P433

Q34492346-8CF1445E-CA31-48A9-AF63-2C2226C5F6E9

P478

Q34492346-1C1834C5-EAD4-4A06-8B55-11B973307929

P50

Q34492346-2C6C6835-78EF-4787-9A9E-99223570C456

Q34492346-ABDAAFE7-E928-4A76-BEF0-9F9E3E80C33C

P577

Q34492346-F30EE70D-ED5C-4F55-9D38-42CF0F1D53B4

P5875

Q34492346-8871AF65-5CF2-4AAB-89B0-D0E466BD27CD

P698

Q34492346-7A887B9F-7F1B-471E-8E5E-C4E589498E72

P932

Q34492346-37D6DDAA-D044-4EA8-BB78-DD15895830DA

P356

ONCOTARGET.4903

P1433

P1476

Functional, chemical genomic, ...... y inhibition in Ewing sarcoma.

@en

P2093

Alyssa L Kennedy

http://www.w3.org/2001/XMLSchema#string

Aviad Tsherniak

http://www.w3.org/2001/XMLSchema#string

Barbara A Weir

http://www.w3.org/2001/XMLSchema#string

Brian Crompton

http://www.w3.org/2001/XMLSchema#string

Francisca Vazquez

http://www.w3.org/2001/XMLSchema#string

Glenn Cowley

http://www.w3.org/2001/XMLSchema#string

Liying Chen

http://www.w3.org/2001/XMLSchema#string

Mounica Vallurupalli

http://www.w3.org/2001/XMLSchema#string

Sudha Parasuraman

http://www.w3.org/2001/XMLSchema#string

Sunkyu Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

The genomic landscape of pediatric Ewing sarcoma.

Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma

Topological domains in mammalian genomes identified by analysis of chromatin interactions

Super-enhancers in the control of cell identity and disease

P304

30178-30193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.4903

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly Stegmaier

P577

2015-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281554793

http://www.w3.org/2001/XMLSchema#string

P698

26337082

http://www.w3.org/2001/XMLSchema#string

P932

4745789

http://www.w3.org/2001/XMLSchema#string